<i>Lactobacillus salivarius</i> AP-32 and <i>Lactobacillus reuteri</i> GL-104 decrease glycemic levels and attenuate diabetes-mediated liver and kidney injury in db/db mice

Our data elucidate a novel role for probiotics in glycemic regulation in the host. <i>L. salivarius</i> AP-32 and <i>L. reuteri</i> GL-104 directly reduce monosaccharide transporter expression in gut cells and have potential as therapeutic probiotics for patients with T2DM.